Who are Placebo then intranasal oxytocin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Oxytocin (Low dose), Cerebrolysin infusion, oxytocin nasal spray, VIP.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/placebo-then-intranasal-oxytocin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Placebo then intranasal oxytocin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Placebo then intranasal oxytocin (Placebo then intranasal oxytocin) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Neuropeptide. Area: Psychiatry/Neurology.

marketed Neuropeptide Oxytocin receptor (OXTR) Psychiatry/Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Placebo then intranasal oxytocin (Placebo then intranasal oxytocin) — MacDonald, Kai, M.D.. Intranasal oxytocin is a neuropeptide that binds to oxytocin receptors in the brain to modulate social cognition, emotional processing, and interpersonal bonding.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Placebo then intranasal oxytocin TARGET	Placebo then intranasal oxytocin	MacDonald, Kai, M.D.	marketed	Neuropeptide	Oxytocin receptor (OXTR)
Oxytocin (Low dose)	Oxytocin (Low dose)	The University of Texas Medical Branch, Galveston	marketed	Neuropeptide agonist	Oxytocin receptor (OXTR)
Cerebrolysin infusion	Cerebrolysin infusion	Clinical Institute of the Brain, Russia	marketed	Neuropeptide mixture
oxytocin nasal spray	oxytocin nasal spray	University of Electronic Science and Technology of China	marketed	Neuropeptide	Oxytocin receptor (OXTR)
VIP	VIP	Danish Headache Center	marketed	Neuropeptide agonist	VIP receptor (VPAC1/VPAC2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Neuropeptide class)

MacDonald, Kai, M.D. · 1 drug in this class
University of Electronic Science and Technology of China · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo then intranasal oxytocin — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-then-intranasal-oxytocin. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab